We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
BACKGROUND Depression is a serious and widespread emotional disorder among the elderly . This study compared the efficacy and safety of bupropion sustained release ( SR ) with the selective serotonin reuptake inhibitor paroxetine in the treatment of major depression in elderly out patients . METHOD Elderly ( > or = 60 years ) out patients with major depressive disorder ( DSM-IV criteria ) were evaluated in this 6-week multicenter , r and omized , double-blind study comparing bupropion SR , 100 - 300 mg/day , and paroxetine , 10 - 40 mg/day . Efficacy was assessed by changes in scores on the Hamilton Rating Scales for Depression ( HAM-D ) and Anxiety ( HAM-A ) and the Clinical Global Impressions-Severity of Illness and -Improvement scales . Safety was assessed by monitoring adverse events , vital signs , and body weight . RESULTS A total of 100 patients ranging in age from 60 to 88 years were r and omly assigned to treatment with bupropion SR ( N = 48 ) or paroxetine ( N = 52 ) . Measurements of efficacy were similar between the 2 treatment groups , with both groups showing improved scores on all depression rating scales . Headache , insomnia , dry mouth , agitation , dizziness , and nausea occurred in > 10 % of patients in both groups ; somnolence , diarrhea , constipation , and anorexia occurred in > 10 % of patients in the paroxetine group . No statistically significant differences between groups in vital signs or weight were found . CONCLUSION Both bupropion SR and paroxetine were safe and effective for the treatment of depression in the elderly . Because of its favorable side effect profile , bupropion SR may provide a safe and effective nonserotonergic treatment alternative that is well suited as an antidepressant for the elderly
We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .